NIH finds new bladder cancer targets

The Cancer Genome Atlas Research Network, a collaboration between two National Institutes of Health groups, has identified new drug targets for bladder cancer that invades the bladder's muscle, a condition the group notes is the deadliest form of the disease, and for which there is no approved second-line therapy.

Researchers also found that the cancer has some genetics in common with some breast, lung, and head & neck cancers, which could help identify new ways to approach the disease.

Among the findings: 

  • Recurrent mutations in 32 genes, nine of which were not previously known to be “significantly mutated"
  • Potential drug targets in 69% of the evaluated tumors
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.